[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634671":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":28,"overallOfficials":13,"centralContacts":13,"locations":13,"responsibleParty":33,"collaborators":13,"id":35,"slug":13,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":13,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":13,"enrollmentInfo":43,"targetDuration":13,"studyType":46,"phases":47,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":58,"whyStopped":13,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":13},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Objective Response Rate (ORR)","Proportion of patients achieving CR or PR per RECIST v1.1","Up to 24 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Patients with recurrent or metastatic cervical cancer who have progressed after at least one line of platinum-based chemotherapy will receive:",[22],{"label":23,"type":24,"description":25,"interventionNames":26},"treatment","EXPERIMENTAL","MRG003 \\[Becotatug vedotin, an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC)\\]: 2.0 mg\u002Fkg IV infusion, Day 1, every 3 weeks QL1706 \\[Iparomlimab and tuvonralimab, a bifunctional anti-programmed death-1\u002Fcytotoxic T-lymphocyte antigen-4 antibody\\]: 5 mg\u002Fkg IV infusion, Day 1, every 3 weeks Each treatment cycle is 21 days. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of new anti-tumor therapy, or death.",[27],"Drug: Treatment",[29],{"type":30,"name":31,"description":25,"armGroupLabels":32,"otherNames":13},"DRUG","Treatment",[23],{"type":34,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100634671",false,"NCT07542717","ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer","A Single-Arm, Multicenter, Phase II Study of MRG003 Combined With QL1706 for Second-Line or Later Treatment of Recurrent or Metastatic Cervical Cancer (ASCERV Study)","Inclusion Criteria:\n\nAge ≥18 years Histologically confirmed recurrent or metastatic cervical cancer (squamous, adenocarcinoma, or adenosquamous) Progression after ≥1 line of platinum-based therapy At least one measurable lesion per RECIST v1.1 ECOG performance status 0-1 Life expectancy ≥12 weeks Adequate organ function Recovery from prior treatment toxicities (≤ Grade 1) Agreement to use effective contraception Signed informed consent\n\nExclusion Criteria:\n\nActive malignancy within 5 years (except certain cured cancers) Active CNS metastases Significant cardiovascular disease Uncontrolled comorbidities Active hepatitis B\u002FC or uncontrolled HIV infection Interstitial lung disease or pneumonitis Prior EGFR-targeted therapy Prior T-cell co-stimulatory pathway agents Recent live vaccination Use of strong CYP3A4 inhibitors\u002Finducers Pregnancy or breastfeeding Any condition deemed unsuitable by investigator","FEMALE","18 Years",{"count":44,"type":45},41,"ESTIMATED","INTERVENTIONAL",[48,49],"PHASE1","PHASE2","This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1\u002FCTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.",[52],"Recurrent or Metastatic Cervical Cancer",[54,55,56,57],"Metastatic Cervical Cancer","MRG003","QL1706","Second-Line or Later Treatment","NOT_YET_RECRUITING","2026-04-17",{"date":61,"type":62},"2026-04-21","ACTUAL",{"date":64,"type":45},"2026-04-10",{"date":66,"type":45},"2030-03-31",{"name":5,"class":6}]